Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: A rhesus monkey study with (S, S)-[18F]FMeNER-D (341 views visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Sep; 36(8): 1308-1314.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 4.531, 5-year impact factor Impact factor a 5 anni: 4.264
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-70349257536&partnerID=40&md5=331ad96015192a19acc4d99fb9c73842
Keywords Parole chiave: Atomoxetine, Norepinephrine Transporter Occupancy, 2 [a (2 Fluoro [2h2] Methoxyphenoxy)benzyl]morpholine F 18, Drug Metabolite, Glucuronidated Atomoxetine, Hydroxylated Atomoxetine, N Noratomoxetine, Noradrenalin Transporter, Radioligand, Radiopharmaceutical Agent, Unclassified Drug, 2 (alpha (2 Fluoromethoxyphenoxy)benzyl)morpholine, 2-(alpha-(2-Fluoromethoxyphenoxy)benzyl)morpholine, Diagnostic Agent, Inhalation Anesthetic Agent, Morpholine Derivative, Propylamine, Animal Experiment, Animal Tissue, Article, Brain Stem, Cingulate Gyrus, Drug Blood Level, Drug Brain Level, Drug Infusion, Drug Protein Binding, Female, Molecular Imaging, Nonhuman, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Rhesus Monkey, Steady State, Thalamus, Dose Response, Macaca, Radioactivity, Scintiscanning, Tissue Distribution, Dose-Response Relationship, Macaca Mulatta, Norepinephrine Plasma Membrane Transport Proteins, Positron-Emission Tomography, 2 [a (2 Fluoro [2h2] Methoxyphenoxy) Benzyl] Morpholine F 18, 2 (alpha (2 Fluoromethoxyphenoxy) Benzyl) Morpholine, 2- (alpha- (2-Fluoromethoxyphenoxy) Benzyl) Morpholine,
Affiliations Affiliazioni:
*** IBB - CNR ***
Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm S-171 76, Sweden
Pfizer Global Research and Development, New London, CT, United States
Novartis Institutes for BioMedical Research, Basel, Switzerland
References Riferimenti:
Tejani-Butt, S.M., Yang, J., Zaffar, H., Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease (1993) Brain Research, 631 (1), pp. 147-150. , DOI 10.1016/0006-8993(93)91201-
Klimek, V., Stockmeier, C., Overholser, J., Meltzer, H.Y., Kalka, S., Dilley, G., Reduced levels of norepinephrine transporters in the locus coeruleus in major depression (1997) J Neurosci, 17, pp. 8451-8458. , 9334417 1:CAS:528:DyaK2sXntVyjur8%3D
Li, W., Knowlton, D., Van Winkle, D.M., Habecker, B.A., Infarction alters both the distribution and noradrenergic properties of cardiac sympathetic neurons (2004) American Journal of Physiology - Heart and Circulatory Physiology, 286, pp. H2229-H2236. , DOI 10.1152/ajpheart.00768.2003
Bobb, A.J., Addington, A.M., Sidransky, E., Gornick, M.C., Lerch, J.P., Greenstein, D.K., Support for association between ADHD and two candidate genes: NET1 and DRD1 (2005) Am J Med Genet B Neuropsychiatr Genet, 134, pp. 67-72
Berzewski, H., Van Moffaert, M., Gagiano, C.A., Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes (1997) European Neuropsychopharmacology, 7 (SUPPL. 1), pp. S37-S47. , DOI 10.1016/S0924-977X(97)00418-5, PII S0924977X97004185
Massana, J., Reboxetine versus fluoxetine: An overview of efficacy and tolerability (1998) J Clin Psychiatry, 59 (SUPPL. 14), pp. 8-10. , 9818624 1:CAS:528:DyaK1cXntFSgtbY%3D
Spencer, T., Biederman, J., Wilens, T., Prince, J., Hatch, M., Jones, J., Harding, M., Seidman, L., Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder (1998) American Journal of Psychiatry, 155 (5), pp. 693-695
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F.R., Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study (2001) Pediatrics, 108, p. 83. , 11694667 10.1542/peds.108.5.e83 1:STN:280:DC%2BD3MnktF2qtw%3D%3D
Bymaster, F.P., Katner, J.S., Nelson, D.L., Hemrick-Luecke, S.K., Threlkeld, P.G., Heiligenstein, J.H., Morin, S.M., Perry, K.W., Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder (2002) Neuropsychopharmacology, 27 (5), pp. 699-711. , DOI 10.1016/S0893-133X(02)00346-9, PII S0893133X02003469
Schou, M., Halldin, C., Sovago, J., Pike, V.W., Gulyas, B., Mozley, P.D., Johnson, D.P., Farde, L., Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER (2003) Nuclear Medicine and Biology, 30 (7), pp. 707-714. , DOI 10.1016/S0969-8051(03)00079-9
Ding, Y.-S., Lin, K.-S., Garza, V., Carter, P., Alexoff, D., Logan, J., Shea, C., King, P., Evaluation of a New Norepinephrine Transporter PET Ligand in Baboons, Both in Brain and Peripheral Organs (2003) Synapse, 50 (4), pp. 345-352. , DOI 10.1002/syn.10281
Seneca, N., Gulyas, B., Varrone, A., Schou, M., Airaksinen, A., Tauscher, J., Vandenhende, F., Halldin, C., Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: A PET study in nonhuman primate brain using (S,S)-[18F] FMeNER-D2 (2006) Psychopharmacology, 188 (1), pp. 119-127. , DOI 10.1007/s00213-006-0483-3
Sureau, F.C., Reader, A.J., Comtat, C., Leroy, C., Ribeiro, M.-J., Buvat, I., Trebossen, R., Impact of image-space resolution modeling for studies with the high-resolution research tomograph (2008) Journal of Nuclear Medicine, 49 (6), pp. 1000-1008. , http://jnm.snmjournals.org/cgi/reprint/49/6/1000, DOI 10.2967/jnumed.107.045351
Varrone, A., Sjoholm, N., Gulyas, B., Halldin, C., Farde, L., Advancement in PET quantification using 3D-OP-OSEM PSF reconstruction with the HRRT (2008) Neuroimage, 41, p. 85. , 10.1016/j.neuroimage.2008.04.054
Hong, I.K., Chung, S.T., Kim, H.K., Kim, Y.B., Son, Y.D., Cho, Z.H., Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction (2007) IEEE Transactions on Medical Imaging, 26 (6), pp. 789-803. , DOI 10.1109/TMI.2007.892644
Clark, J.D., Gebhart, G.F., Gonder, J.C., Keeling, M.E., Kohn, D.F., Special Report: The 1996 Guide for the Care and Use of Laboratory Animals (1997) ILAR J, 38, pp. 41-48. , 11528046
Karlsson, P., Farde, L., Halldin, C., Swahn, C.-G., Sedvall, G., Foged, C., Hansen, K.T., Skrumsager, B., PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor (1993) Psychopharmacology, 113 (2), pp. 149-156. , DOI 10.1007/BF02245691
Lammertsma, A.A., Hume, S.P., Simplified reference tissue model for PET receptor studies (1996) NeuroImage, 4 (3), pp. 153-158. , DOI 10.1006/nimg.1996.0066
Ichise, M., Liow, J.S., Lu, J.Q., Takano, A., Model, K., Toyama, H., Linearized reference tissue parametric imaging methods: Application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain (2003) Cereb Blood Flow Metab, 23, pp. 1096-1112
Swanson, L.W., Hartman, B.K., The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker (1975) J Comp Neurol, 163, pp. 467-505. , 1100685 10.1002/cne.901630406 1:STN:280:DyaE28%2FisFGksg%3D%3D
Farde, L., Wiesel, F.A., Nordström, A.L., Sedvall, G., D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics (1989) Psychopharmacology (Berl), 99, pp. 28-S31. , 10.1007/BF00442555
Witcher, J.W., Long, A., Smith, B., Sauer, J.M., Heilgenstein, J., Wilens, T., Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder (2003) J Child Adolesc Psychopharmacol, 13, pp. 53-63. , 12804126 10.1089/104454603321666199
Takano, A., Suhara, T., Ikoma, Y., Yasuno, F., Maeda, J., Ichimiya, T., Sudo, Y., Okubo, Y., Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics (2004) International Journal of Neuropsychopharmacology, 7 (1), pp. 19-26. , DOI 10.1017/S1461145703003912
Takano, A., Gulyas, B., Varrone, A., Karlsson, P., Schou, M., Airaksinen, A.J., Vandenhende, F., Halldin, C., Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 (2008) European Journal of Nuclear Medicine and Molecular Imaging, 35 (1), pp. 153-157. , DOI 10.1007/s00259-007-0598-8
Takano, A., Halldin, C., Varrone, A., Karlsson, P., Sjöholm, N., Stubbs, J.B., Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: A human whole-body PET study (2008) Eur J Nucl Med Mol Imaging, 35, pp. 630-636. , 18000665 10.1007/s00259-007-0622-z 1:CAS:528:DC%2BD1cXjvFOgt78%3D
Takano, A., Varrone, A., Gulyás, B., Karlsson, P., Tauscher, J., Halldin, C., Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2 (2008) Neuroimage, 42, pp. 474-482. , 18617423 10.1016/j.neuroimage.2008.05.040
Arakawa, R., Okumura, M., Ito, H., Seki, C., Takahashi, H., Takano, H., Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2 (2008) J Nucl Med, 49, pp. 1270-1276. , 18632811 10.2967/jnumed.108.051292
Kubota, T., Hirota, K., Yoshida, H., Takahashi, S., Anzawa, N., Ohkawa, H., Kushikata, T., Matsuki, A., Effects of sedatives on noradrenaline release from the medial prefrontal cortex in rats (1999) Psychopharmacology, 146 (3), pp. 335-338. , DOI 10.1007/s002130051125
Anzawa, N., Kushikata, T., Ohkawa, H., Yoshida, H., Kubota, T., Matsuki, A., Increased noradrenaline release from rat preoptic area during and after sevoflurane and isoflurane anesthesia (2001) Can J Anaesth, 48, pp. 462-465. , 11394514 10.1007/BF03028309 1:STN:280:DC%2BD3Mzislequg%3D%3D
Kushikata, T., Hirota, K., Kotani, N., Yoshida, H., Kudo, M., Matsuki, A., Isoflurane increases norepinephrine release in the rat preoptic area and the posterior hypothalamus in vivo and in vitro: Relevance to thermoregulation during anesthesia (2005) Neuroscience, 131 (1), pp. 79-86. , DOI 10.1016/j.neuroscience.2004.11.007, PII S0306452204010814
Tejani-Butt, S. M., Yang, J., Zaffar, H., Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease (1993) Brain Research, 631 (1), pp. 147-150. , DOI 10. 1016/0006-8993 (93) 91201-
Bobb, A. J., Addington, A. M., Sidransky, E., Gornick, M. C., Lerch, J. P., Greenstein, D. K., Support for association between ADHD and two candidate genes: NET1 and DRD1 (2005) Am J Med Genet B Neuropsychiatr Genet, 134, pp. 67-72
Bymaster, F. P., Katner, J. S., Nelson, D. L., Hemrick-Luecke, S. K., Threlkeld, P. G., Heiligenstein, J. H., Morin, S. M., Perry, K. W., Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder (2002) Neuropsychopharmacology, 27 (5), pp. 699-711. , DOI 10. 1016/S0893-133X (02) 00346-9, PII S0893133X02003469
Ding, Y. -S., Lin, K. -S., Garza, V., Carter, P., Alexoff, D., Logan, J., Shea, C., King, P., Evaluation of a New Norepinephrine Transporter PET Ligand in Baboons, Both in Brain and Peripheral Organs (2003) Synapse, 50 (4), pp. 345-352. , DOI 10. 1002/syn. 10281
Sureau, F. C., Reader, A. J., Comtat, C., Leroy, C., Ribeiro, M. -J., Buvat, I., Trebossen, R., Impact of image-space resolution modeling for studies with the high-resolution research tomograph (2008) Journal of Nuclear Medicine, 49 (6), pp. 1000-1008. , http: //jnm. snmjournals. org/cgi/reprint/49/6/1000, DOI 10. 2967/jnumed. 107. 045351
Hong, I. K., Chung, S. T., Kim, H. K., Kim, Y. B., Son, Y. D., Cho, Z. H., Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction (2007) IEEE Transactions on Medical Imaging, 26 (6), pp. 789-803. , DOI 10. 1109/TMI. 2007. 892644
Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., Kohn, D. F., Special Report: The 1996 Guide for the Care and Use of Laboratory Animals (1997) ILAR J, 38, pp. 41-48. , 11528046
Lammertsma, A. A., Hume, S. P., Simplified reference tissue model for PET receptor studies (1996) NeuroImage, 4 (3), pp. 153-158. , DOI 10. 1006/nimg. 1996. 0066
Swanson, L. W., Hartman, B. K., The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker (1975) J Comp Neurol, 163, pp. 467-505. , 1100685 10. 1002/cne. 901630406 1: STN: 280: DyaE28%2FisFGksg%3D%3D
Witcher, J. W., Long, A., Smith, B., Sauer, J. M., Heilgenstein, J., Wilens, T., Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder (2003) J Child Adolesc Psychopharmacol, 13, pp. 53-63. , 12804126 10. 1089/104454603321666199
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Sep; 36(8): 1308-1314.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 4.531, 5-year impact factor Impact factor a 5 anni: 4.264
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-70349257536&partnerID=40&md5=331ad96015192a19acc4d99fb9c73842
Keywords Parole chiave: Atomoxetine, Norepinephrine Transporter Occupancy, 2 [a (2 Fluoro [2h2] Methoxyphenoxy)benzyl]morpholine F 18, Drug Metabolite, Glucuronidated Atomoxetine, Hydroxylated Atomoxetine, N Noratomoxetine, Noradrenalin Transporter, Radioligand, Radiopharmaceutical Agent, Unclassified Drug, 2 (alpha (2 Fluoromethoxyphenoxy)benzyl)morpholine, 2-(alpha-(2-Fluoromethoxyphenoxy)benzyl)morpholine, Diagnostic Agent, Inhalation Anesthetic Agent, Morpholine Derivative, Propylamine, Animal Experiment, Animal Tissue, Article, Brain Stem, Cingulate Gyrus, Drug Blood Level, Drug Brain Level, Drug Infusion, Drug Protein Binding, Female, Molecular Imaging, Nonhuman, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Rhesus Monkey, Steady State, Thalamus, Dose Response, Macaca, Radioactivity, Scintiscanning, Tissue Distribution, Dose-Response Relationship, Macaca Mulatta, Norepinephrine Plasma Membrane Transport Proteins, Positron-Emission Tomography, 2 [a (2 Fluoro [2h2] Methoxyphenoxy) Benzyl] Morpholine F 18, 2 (alpha (2 Fluoromethoxyphenoxy) Benzyl) Morpholine, 2- (alpha- (2-Fluoromethoxyphenoxy) Benzyl) Morpholine,
Affiliations Affiliazioni:
*** IBB - CNR ***
Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm S-171 76, Sweden
Pfizer Global Research and Development, New London, CT, United States
Novartis Institutes for BioMedical Research, Basel, Switzerland
References Riferimenti:
Tejani-Butt, S.M., Yang, J., Zaffar, H., Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease (1993) Brain Research, 631 (1), pp. 147-150. , DOI 10.1016/0006-8993(93)91201-
Klimek, V., Stockmeier, C., Overholser, J., Meltzer, H.Y., Kalka, S., Dilley, G., Reduced levels of norepinephrine transporters in the locus coeruleus in major depression (1997) J Neurosci, 17, pp. 8451-8458. , 9334417 1:CAS:528:DyaK2sXntVyjur8%3D
Li, W., Knowlton, D., Van Winkle, D.M., Habecker, B.A., Infarction alters both the distribution and noradrenergic properties of cardiac sympathetic neurons (2004) American Journal of Physiology - Heart and Circulatory Physiology, 286, pp. H2229-H2236. , DOI 10.1152/ajpheart.00768.2003
Bobb, A.J., Addington, A.M., Sidransky, E., Gornick, M.C., Lerch, J.P., Greenstein, D.K., Support for association between ADHD and two candidate genes: NET1 and DRD1 (2005) Am J Med Genet B Neuropsychiatr Genet, 134, pp. 67-72
Berzewski, H., Van Moffaert, M., Gagiano, C.A., Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes (1997) European Neuropsychopharmacology, 7 (SUPPL. 1), pp. S37-S47. , DOI 10.1016/S0924-977X(97)00418-5, PII S0924977X97004185
Massana, J., Reboxetine versus fluoxetine: An overview of efficacy and tolerability (1998) J Clin Psychiatry, 59 (SUPPL. 14), pp. 8-10. , 9818624 1:CAS:528:DyaK1cXntFSgtbY%3D
Spencer, T., Biederman, J., Wilens, T., Prince, J., Hatch, M., Jones, J., Harding, M., Seidman, L., Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder (1998) American Journal of Psychiatry, 155 (5), pp. 693-695
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F.R., Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study (2001) Pediatrics, 108, p. 83. , 11694667 10.1542/peds.108.5.e83 1:STN:280:DC%2BD3MnktF2qtw%3D%3D
Bymaster, F.P., Katner, J.S., Nelson, D.L., Hemrick-Luecke, S.K., Threlkeld, P.G., Heiligenstein, J.H., Morin, S.M., Perry, K.W., Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder (2002) Neuropsychopharmacology, 27 (5), pp. 699-711. , DOI 10.1016/S0893-133X(02)00346-9, PII S0893133X02003469
Schou, M., Halldin, C., Sovago, J., Pike, V.W., Gulyas, B., Mozley, P.D., Johnson, D.P., Farde, L., Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER (2003) Nuclear Medicine and Biology, 30 (7), pp. 707-714. , DOI 10.1016/S0969-8051(03)00079-9
Ding, Y.-S., Lin, K.-S., Garza, V., Carter, P., Alexoff, D., Logan, J., Shea, C., King, P., Evaluation of a New Norepinephrine Transporter PET Ligand in Baboons, Both in Brain and Peripheral Organs (2003) Synapse, 50 (4), pp. 345-352. , DOI 10.1002/syn.10281
Seneca, N., Gulyas, B., Varrone, A., Schou, M., Airaksinen, A., Tauscher, J., Vandenhende, F., Halldin, C., Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: A PET study in nonhuman primate brain using (S,S)-[18F] FMeNER-D2 (2006) Psychopharmacology, 188 (1), pp. 119-127. , DOI 10.1007/s00213-006-0483-3
Sureau, F.C., Reader, A.J., Comtat, C., Leroy, C., Ribeiro, M.-J., Buvat, I., Trebossen, R., Impact of image-space resolution modeling for studies with the high-resolution research tomograph (2008) Journal of Nuclear Medicine, 49 (6), pp. 1000-1008. , http://jnm.snmjournals.org/cgi/reprint/49/6/1000, DOI 10.2967/jnumed.107.045351
Varrone, A., Sjoholm, N., Gulyas, B., Halldin, C., Farde, L., Advancement in PET quantification using 3D-OP-OSEM PSF reconstruction with the HRRT (2008) Neuroimage, 41, p. 85. , 10.1016/j.neuroimage.2008.04.054
Hong, I.K., Chung, S.T., Kim, H.K., Kim, Y.B., Son, Y.D., Cho, Z.H., Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction (2007) IEEE Transactions on Medical Imaging, 26 (6), pp. 789-803. , DOI 10.1109/TMI.2007.892644
Clark, J.D., Gebhart, G.F., Gonder, J.C., Keeling, M.E., Kohn, D.F., Special Report: The 1996 Guide for the Care and Use of Laboratory Animals (1997) ILAR J, 38, pp. 41-48. , 11528046
Karlsson, P., Farde, L., Halldin, C., Swahn, C.-G., Sedvall, G., Foged, C., Hansen, K.T., Skrumsager, B., PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor (1993) Psychopharmacology, 113 (2), pp. 149-156. , DOI 10.1007/BF02245691
Lammertsma, A.A., Hume, S.P., Simplified reference tissue model for PET receptor studies (1996) NeuroImage, 4 (3), pp. 153-158. , DOI 10.1006/nimg.1996.0066
Ichise, M., Liow, J.S., Lu, J.Q., Takano, A., Model, K., Toyama, H., Linearized reference tissue parametric imaging methods: Application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain (2003) Cereb Blood Flow Metab, 23, pp. 1096-1112
Swanson, L.W., Hartman, B.K., The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker (1975) J Comp Neurol, 163, pp. 467-505. , 1100685 10.1002/cne.901630406 1:STN:280:DyaE28%2FisFGksg%3D%3D
Farde, L., Wiesel, F.A., Nordström, A.L., Sedvall, G., D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics (1989) Psychopharmacology (Berl), 99, pp. 28-S31. , 10.1007/BF00442555
Witcher, J.W., Long, A., Smith, B., Sauer, J.M., Heilgenstein, J., Wilens, T., Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder (2003) J Child Adolesc Psychopharmacol, 13, pp. 53-63. , 12804126 10.1089/104454603321666199
Takano, A., Suhara, T., Ikoma, Y., Yasuno, F., Maeda, J., Ichimiya, T., Sudo, Y., Okubo, Y., Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics (2004) International Journal of Neuropsychopharmacology, 7 (1), pp. 19-26. , DOI 10.1017/S1461145703003912
Takano, A., Gulyas, B., Varrone, A., Karlsson, P., Schou, M., Airaksinen, A.J., Vandenhende, F., Halldin, C., Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 (2008) European Journal of Nuclear Medicine and Molecular Imaging, 35 (1), pp. 153-157. , DOI 10.1007/s00259-007-0598-8
Takano, A., Halldin, C., Varrone, A., Karlsson, P., Sjöholm, N., Stubbs, J.B., Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: A human whole-body PET study (2008) Eur J Nucl Med Mol Imaging, 35, pp. 630-636. , 18000665 10.1007/s00259-007-0622-z 1:CAS:528:DC%2BD1cXjvFOgt78%3D
Takano, A., Varrone, A., Gulyás, B., Karlsson, P., Tauscher, J., Halldin, C., Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2 (2008) Neuroimage, 42, pp. 474-482. , 18617423 10.1016/j.neuroimage.2008.05.040
Arakawa, R., Okumura, M., Ito, H., Seki, C., Takahashi, H., Takano, H., Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2 (2008) J Nucl Med, 49, pp. 1270-1276. , 18632811 10.2967/jnumed.108.051292
Kubota, T., Hirota, K., Yoshida, H., Takahashi, S., Anzawa, N., Ohkawa, H., Kushikata, T., Matsuki, A., Effects of sedatives on noradrenaline release from the medial prefrontal cortex in rats (1999) Psychopharmacology, 146 (3), pp. 335-338. , DOI 10.1007/s002130051125
Anzawa, N., Kushikata, T., Ohkawa, H., Yoshida, H., Kubota, T., Matsuki, A., Increased noradrenaline release from rat preoptic area during and after sevoflurane and isoflurane anesthesia (2001) Can J Anaesth, 48, pp. 462-465. , 11394514 10.1007/BF03028309 1:STN:280:DC%2BD3Mzislequg%3D%3D
Kushikata, T., Hirota, K., Kotani, N., Yoshida, H., Kudo, M., Matsuki, A., Isoflurane increases norepinephrine release in the rat preoptic area and the posterior hypothalamus in vivo and in vitro: Relevance to thermoregulation during anesthesia (2005) Neuroscience, 131 (1), pp. 79-86. , DOI 10.1016/j.neuroscience.2004.11.007, PII S0306452204010814
Tejani-Butt, S. M., Yang, J., Zaffar, H., Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease (1993) Brain Research, 631 (1), pp. 147-150. , DOI 10. 1016/0006-8993 (93) 91201-
Bobb, A. J., Addington, A. M., Sidransky, E., Gornick, M. C., Lerch, J. P., Greenstein, D. K., Support for association between ADHD and two candidate genes: NET1 and DRD1 (2005) Am J Med Genet B Neuropsychiatr Genet, 134, pp. 67-72
Bymaster, F. P., Katner, J. S., Nelson, D. L., Hemrick-Luecke, S. K., Threlkeld, P. G., Heiligenstein, J. H., Morin, S. M., Perry, K. W., Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder (2002) Neuropsychopharmacology, 27 (5), pp. 699-711. , DOI 10. 1016/S0893-133X (02) 00346-9, PII S0893133X02003469
Ding, Y. -S., Lin, K. -S., Garza, V., Carter, P., Alexoff, D., Logan, J., Shea, C., King, P., Evaluation of a New Norepinephrine Transporter PET Ligand in Baboons, Both in Brain and Peripheral Organs (2003) Synapse, 50 (4), pp. 345-352. , DOI 10. 1002/syn. 10281
Sureau, F. C., Reader, A. J., Comtat, C., Leroy, C., Ribeiro, M. -J., Buvat, I., Trebossen, R., Impact of image-space resolution modeling for studies with the high-resolution research tomograph (2008) Journal of Nuclear Medicine, 49 (6), pp. 1000-1008. , http: //jnm. snmjournals. org/cgi/reprint/49/6/1000, DOI 10. 2967/jnumed. 107. 045351
Hong, I. K., Chung, S. T., Kim, H. K., Kim, Y. B., Son, Y. D., Cho, Z. H., Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction (2007) IEEE Transactions on Medical Imaging, 26 (6), pp. 789-803. , DOI 10. 1109/TMI. 2007. 892644
Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., Kohn, D. F., Special Report: The 1996 Guide for the Care and Use of Laboratory Animals (1997) ILAR J, 38, pp. 41-48. , 11528046
Lammertsma, A. A., Hume, S. P., Simplified reference tissue model for PET receptor studies (1996) NeuroImage, 4 (3), pp. 153-158. , DOI 10. 1006/nimg. 1996. 0066
Swanson, L. W., Hartman, B. K., The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker (1975) J Comp Neurol, 163, pp. 467-505. , 1100685 10. 1002/cne. 901630406 1: STN: 280: DyaE28%2FisFGksg%3D%3D
Witcher, J. W., Long, A., Smith, B., Sauer, J. M., Heilgenstein, J., Wilens, T., Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder (2003) J Child Adolesc Psychopharmacol, 13, pp. 53-63. , 12804126 10. 1089/104454603321666199
Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: A rhesus monkey study with (S, S)-[18F]FMeNER-D
Purpose: In a previous PET study on norepinephrine transporter (NET) occupancy in the nonhuman primate brain, the relationship between NET occupancy and atomoxetine plasma concentration, and occupancies among different brain regions, were not demonstrated adequately. It may therefore be difficult to translate the results to the clinical situations. In the present study, the detailed change of NET occupancy was investigated among a wider range of doses in a more advanced manner. Methods: Two rhesus monkeys were examined using a high-resolution PET system with (S,S)-[18F]FMeNER-D2 under baseline conditions and after steady-state infusion of different doses of atomoxetine (0.003 to 0.12 mg/kg per hour). NET occupancy of the thalamus, brainstem and anterior cingulate cortex was calculated using BPND obtained with the simplified reference tissue model. Results: NET occupancy increased regionally and uniformly as the plasma concentration of atomoxetine increased. The estimated Kd value (the amount to occupy 50% of NET) in the thalamus was 16 ng/ml. Conclusion: The results indicate that clinical doses of atomoxetine would occupy NET almost completely. © 2009 Springer-Verlag.
Purpose: In a previous PET study on norepinephrine transporter (NET) occupancy in the nonhuman primate brain, the relationship between NET occupancy and atomoxetine plasma concentration, and occupancies among different brain regions, were not demonstrated adequately. It may therefore be difficult to translate the results to the clinical situations. In the present study, the detailed change of NET occupancy was investigated among a wider range of doses in a more advanced manner. Methods: Two rhesus monkeys were examined using a high-resolution PET system with (S,S)-[18F]FMeNER-D2 under baseline conditions and after steady-state infusion of different doses of atomoxetine (0.003 to 0.12 mg/kg per hour). NET occupancy of the thalamus, brainstem and anterior cingulate cortex was calculated using BPND obtained with the simplified reference tissue model. Results: NET occupancy increased regionally and uniformly as the plasma concentration of atomoxetine increased. The estimated Kd value (the amount to occupy 50% of NET) in the thalamus was 16 ng/ml. Conclusion: The results indicate that clinical doses of atomoxetine would occupy NET almost completely. © 2009 Springer-Verlag.
Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: A rhesus monkey study with (S, S)-[18F]FMeNER-D
No results. Nessun risultato. |
Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: A rhesus monkey study with (S, S)-[18F]FMeNER-D
Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T, Suzuki M, Fujiwara H, Takahashi H, Nakao R, Fukumura T, Varrone A, Halldin C, Nishikawa T, Suhara T
* Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I (367 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Jul; 53(7): 1065-1073.
Impact Factor: 5.774
Dettagli Esporta in BibTeX Esporta in EndNote
Takano A, Varrone A, Gulyas B, Karlsson P, Tauscher J, Halldin C
* Mapping of the norepinephrine transporter in man using PET with (S, S)-[F-18]FMeNER-D-2 (249 visite) (PDF 199 visite)
Neuroimage (ISSN: 1053-8119, 1053-8119linking), 2008 Sep 15; 41: 474-482.
Impact Factor: 5.694
Dettagli Esporta in BibTeX Esporta in EndNote
Takano A, Halldin C, Varrone A, Karlsson P, Sjoholm N, Stubbs JB, Schou M, Airaksinen AJ, Tauscher J, Gulyas B
* Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S, S)-[18F]FMeNER-D2: A human whole-body PET study (233 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Mar; 35(3): 630-636.
Impact Factor: 4.532
Dettagli Esporta in BibTeX Esporta in EndNote
Takano A, Gulyas B, Varrone A, Karlsson P, Schou M, Airaksinen AJ, Vandenhende F, Tauscher J, Halldin C
* Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S, S)-[18F]FMeNER-D2 (285 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Jan; 35(1): 153-157.
Impact Factor: 4.532
Dettagli Esporta in BibTeX Esporta in EndNote
Seneca N, Gulyas B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis R, Halldin C
* Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: A PET study in nonhuman primate brain using (S, S)-[18F] FMeNER-D2 (377 visite)
Psychopharmacology (ISSN: 0033-3158), 2006 Sep; 188(1): 119-127.
Impact Factor: 3.625
Dettagli Esporta in BibTeX Esporta in EndNote
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T, Suzuki M, Fujiwara H, Takahashi H, Nakao R, Fukumura T, Varrone A, Halldin C, Nishikawa T, Suhara T
* Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I (367 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Jul; 53(7): 1065-1073.
Impact Factor: 5.774
Dettagli Esporta in BibTeX Esporta in EndNote
Takano A, Varrone A, Gulyas B, Karlsson P, Tauscher J, Halldin C
* Mapping of the norepinephrine transporter in man using PET with (S, S)-[F-18]FMeNER-D-2 (249 visite) (PDF 199 visite)
Neuroimage (ISSN: 1053-8119, 1053-8119linking), 2008 Sep 15; 41: 474-482.
Impact Factor: 5.694
Dettagli Esporta in BibTeX Esporta in EndNote
Takano A, Halldin C, Varrone A, Karlsson P, Sjoholm N, Stubbs JB, Schou M, Airaksinen AJ, Tauscher J, Gulyas B
* Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S, S)-[18F]FMeNER-D2: A human whole-body PET study (233 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Mar; 35(3): 630-636.
Impact Factor: 4.532
Dettagli Esporta in BibTeX Esporta in EndNote
Takano A, Gulyas B, Varrone A, Karlsson P, Schou M, Airaksinen AJ, Vandenhende F, Tauscher J, Halldin C
* Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S, S)-[18F]FMeNER-D2 (285 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Jan; 35(1): 153-157.
Impact Factor: 4.532
Dettagli Esporta in BibTeX Esporta in EndNote
Seneca N, Gulyas B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis R, Halldin C
* Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: A PET study in nonhuman primate brain using (S, S)-[18F] FMeNER-D2 (377 visite)
Psychopharmacology (ISSN: 0033-3158), 2006 Sep; 188(1): 119-127.
Impact Factor: 3.625
Dettagli Esporta in BibTeX Esporta in EndNote
5 Records (5 escludendo Abstract e Conferenze).
Impact factor totale: 24.157 (24.157 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 26.677 (26.677 escludendo Abstract e Conferenze).
Impact factor totale: 24.157 (24.157 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 26.677 (26.677 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:15:01
341 views visite. Last view on Ultima visita in data Tuesday 11 May 2021, 10:30:25
ibb.cnr.it